GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Estrella Immunopharma ESLA · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.51

+36.93%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$13.1m

FY2020FY2025

Free cash flow

−$1.8m

FY2020FY2025

Shareholders' equity

−$10.4m

FY2020FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Research and development$10.2m$6.4m$4.1m$10.5m$1.4m$457,231
Operating income−$13.1m−$8.8m−$7.3m−$11.1m−$1.7m−$733,693
Net income−$13.1m−$8.8m−$7.3m−$11.1m−$1.7m−$733,693
Diluted earnings per share-0.34-0.24-0.21-0.32-0.05-0.02

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Total assets$3.2m$3.1m$4.5m$10.0m$4.9m—
Cash and short-term investments$1.4m$916,916—$40,802$4.1m—
Total liabilities$13.5m$3.0m$180,701$2.9m$6.0m—
Debt———$498,600——
Shareholders' equity−$10.4m$143,731$4.3m$7.1m−$1.0m—
Shares outstanding38m37m35m35m35m43m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations−$1.8m−$3.1m−$16.1m−$1.0m−$1.4m−$670,820
Capital spending—−$4————
Free cash flow−$1.8m−$3.1m−$16.1m−$1.0m−$1.4m−$670,820

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Operating income−$2.1m−$2.3m−$613,199−$4.8m−$5.5m−$2.1m−$1.1m−$3.4m
Net income−$2.3m−$2.3m−$613,174−$4.8m−$5.5m−$2.1m−$1.1m−$3.4m
Diluted earnings per share-0.05-0.05-0.02-0.13-0.15-0.06-0.03-0.09
Cash from operations−$1.0m−$6.0m—————−$2.0m
Total assets$1.8m$3.7m$3.2m$3.5m$3.0m$2.4m$3.1m$3.7m
Cash and short-term investments$146,670$1.9m$1.4m$1.6m$1.3m$421,473$916,916$1.8m
Debt———$4,000$4,000$10,000—$4,000
Shareholders' equity−$7.4m−$5.3m−$10.4m−$9.8m−$6.1m−$1.8m$143,731$746,286

Growth per year

Compound annual rate

3 years5 years10 years
Operating income5.5%77.9%—
Net income5.5%77.9%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-4.5-5.0-5.3-7.3-46.0

Share price return

Finished calendar years

20252024202320222021
Return40%-8%-46%4%1%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 1-to-1 reverse split · 2 Oct 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.